Argeris Karabelas will become the new chairman of the board of directors of Human Genome Sciences next month, replacing William Haseltime after his retirement, the company said on Monday. Karabelas is a partner of investment firm Care Capital and has been a director of Human Genome Sciences since 2002. He holds a PhD in pharmacokinetics from the Massachusetts College of Pharmacy. In addition, Human Genome Sciences has promoted Craig Rosen to president and chief operating officer, from president for research and development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.